Back to results
US 2026/0070962 A1Published application
Chimeric antigen receptors for removal of amyloid
AssigneeUniversity of Tennessee Research Foundation
InventorsJames S. FOSTER, Manasi BALACHANDRAN, Jonathan S. WALL
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric receptors comprising an amyloid-reactive peptide, as well as cells comprising the chimeric receptors. Also provided herein are methods of treating amyloid-based diseases by administering a cell comprising a chimeric receptor described herein.
Claims57
An engineered cell comprising a chimeric receptor comprising from N-terminal to C-terminal direction,
- (i) an amyloid-reactive peptide;
- (ii) a CH3 domain or fragment thereof;
- (iii) a transmembrane domain;
- and
- (iv) a cytoplasmic domain, wherein the cytoplasmic domain comprises an intracellular signaling domain.
2 more elements
An engineered cell comprising a chimeric receptor comprising from N-terminal to C-terminal direction,
- an amyloid-reactive peptide;
- a human CH2 domain comprising an amino acid sequence having at least 80, 85, 90, 95, 97, 98, or 99% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 21;
- a transmembrane domain;
- and
- a cytoplasmic domain, wherein the cytoplasmic domain comprises an intracellular signaling domain.
3 more elements
A chimeric receptor comprising from N-terminal to C-terminal direction,
- (i) an amyloid-reactive peptide;
- (ii) a CH3 domain or fragment thereof;
- (iii) a transmembrane domain;
- and
- (iv) a cytoplasmic domain, wherein the cytoplasmic domain comprises an intracellular signaling domain.
2 more elements
Dependencies are inferred from the claim text.